Vaxxas, a clinical-stage biotechnology company, has achieved a significant milestone in vaccine delivery technology. The company’s innovative high-density microarray patch (HD-MAP) technology, which enables vaccines to be administered through a skin patch, has shown positive results in a human clinical trial.

Clinical Trial by University of the Sunshine Coast Reveals Encouraging Data

Conducted by the University of the Sunshine Coast in Queensland, Australia, the trial involved 60 young, healthy adults. It compared the immune response of those receiving a measles and rubella (MR) vaccine via the HD-MAP patch with those given the vaccine through traditional needle and syringe methods. The study reported a significant increase in neutralizing antibodies in participants who received the HD-MAP vaccine, comparable to the response from the standard method. Importantly, there were no serious adverse events related to the treatment in any study group.

Potential Advantages of HD-MAP Technology in Vaccine Distribution

The Vaxxas HD-MAP employs microprojections to deliver the vaccine directly under the skin, potentially enhancing immune responses. This method also offers advantages in vaccine storage and transportation, as it could reduce the need for refrigeration. The ease of administration, including the possibility of self-administration, is another significant benefit.

David Hoey, CEO of Vaxxas, expressed optimism about the trial results, noting their implications for global health, especially in parts of the world where measles and rubella are still prevalent. He emphasized the potential of the HD-MAP technology to facilitate vaccination in hard-to-reach communities, especially in lower- and middle-income countries.

Vaxxas to Progress to Phase I/II Clinical Trials in Africa

Following the successful trial, Vaxxas is planning a Phase I/II clinical trial in The Gambia, Africa, to further investigate the safety and efficacy of the HD-MAP technology. This trial, which will focus on infants not previously immunized against measles or rubella, is part of Vaxxas’ expanding clinical pipeline that includes vaccines for COVID-19, influenza, and typhoid.

Support and Funding from the Bill & Melinda Gates Foundation

The clinical trial and upcoming studies have been supported by grants from the Bill & Melinda Gates Foundation, highlighting the foundation’s commitment to innovative solutions in global health.

Conclusion: A New Horizon in Vaccine Delivery

Vaxxas’ successful trial marks a potential turning point in vaccine administration, with its skin patch technology poised to revolutionize how vaccines are delivered worldwide, enhancing global health outcomes.

  David Hoey, HD-MAP skin patch, Vaxxas